Robert Hawkins
Chief Tech/Sci/R&D Officer en INSTIL BIO, INC. .
Fortuna: 31 977 $ al 31/03/2024
Perfil
Robert Edward Hawkins is the founder of Instil Bio (UK) Ltd.
He currently holds the position of Head-Research & Development at Instil Bio, Inc. and Independent Non-Executive Director at BiVictriX Therapeutics Plc.
In the past, he served as a Director at Instil Bio, Inc. and as an Independent Non-Executive Director at Motif Bio Plc.
He was also an Honorary Professor at The University of Manchester.
Hawkins received his undergraduate and doctorate degrees from the University of Cambridge and his doctorate degree from University College London.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 31/12/2022 | 225 000 ( 0.27% ) | 31 977 $ | 31/03/2024 |
Cargos activos de Robert Hawkins
| Empresas | Cargo | Inicio |
|---|---|---|
| BIVICTRIX THERAPEUTICS PLC | Director/Board Member | 22/09/2021 |
| INSTIL BIO, INC. | Chief Tech/Sci/R&D Officer | 11/11/2022 |
Antiguos cargos conocidos de Robert Hawkins.
| Empresas | Cargo | Fin |
|---|---|---|
| INSTIL BIO, INC. | Director/Board Member | 01/07/2020 |
| Instil Bio (UK) Ltd. | Chief Executive Officer | 01/01/2020 |
| The University of Manchester | Corporate Officer/Principal | - |
| MOTIF BIO PLC | Director/Board Member | - |
Formación de Robert Hawkins.
| University of Cambridge | Doctorate Degree |
| University College London | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BIVICTRIX THERAPEUTICS PLC | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
| Instil Bio (UK) Ltd. | |
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Robert Hawkins
